ERBB2 and breast cancer: Recent studies are now implementing this algorithm in BC H&E-stained WSIs, demonstrating that it can effectively differentiate between breast cancers lacking both the HER2 protein and mRNA (HER2-null) and tumors with low levels of HER2 expression [112].